MNG145
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.516
- HYPOXIA+0.267
- MYOGENESIS+0.226
- KRAS_SIGNALING_DN+0.225
- WNT_BETA_CATENIN_SIGNALING+0.206
- APICAL_SURFACE+0.204
- ANGIOGENESIS+0.203
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.203
- COAGULATION+0.170
- KRAS_SIGNALING_UP+0.164
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.541
- MYC_TARGETS_V1-0.501
- MYC_TARGETS_V2-0.468
- E2F_TARGETS-0.444
- DNA_REPAIR-0.425
- INTERFERON_ALPHA_RESPONSE-0.424
- FATTY_ACID_METABOLISM-0.386
- PI3K_AKT_MTOR_SIGNALING-0.359
- CHOLESTEROL_HOMEOSTASIS-0.347
- PEROXISOME-0.345
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG888 | — | — | 0.906 |
| 2 | MNG831 | — | — | 0.900 |
| 3 | C3N-00175 | — | cohortA1 | 0.894 |
| 4 | TCGA-MN-A4N4-01A-12R-A24X-07 | — | cohortA1 | 0.892 |
| 5 | TCGA-63-A5MG-01A-12R-A27Q-07 | — | cohortSQ1 | 0.888 |
| 6 | R116 | — | — | 0.873 |
| 7 | SRR9879289 | — | cohortSQ1 | 0.868 |
| 8 | SRR4296064 | — | cohortA1 | 0.866 |
| 9 | MNG1152 | — | — | 0.866 |
| 10 | SRR1516041 | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.516 | Inavolisib | — uncovered |
| HYPOXIA | 0.267 | Idelalisib | — uncovered |
| MYOGENESIS | 0.226 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.225 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.206 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.204 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.203 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.203 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.164 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.122 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.107 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.102 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.092 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.052 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.043 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.034 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.033 | Inavolisib | — uncovered |